CATALYST PHARMACEUTICALS PARTNERS
Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapseâ„¢ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapseâ„¢ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.
CATALYST PHARMACEUTICALS PARTNERS
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical
Founded:
2002-01-01
Address:
Coral Gables, Florida, United States
Country:
United States
Website Url:
http://www.catalystpharma.com
Total Employee:
11+
Status:
Active
Contact:
3055290933
Email Addresses:
[email protected]
Total Funding:
133.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Peplin
Peplin is a specialty pharmaceutical company focused on advancing and commercializing medical dermatology products.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Post-IPO Equity - Catalyst Pharmaceuticals Partners
Official Site Inspections
http://www.catalystpharma.com Semrush global rank: 2.69 M Semrush visits lastest month: 6.17 K
- Host name: 172.67.215.2
- IP address: 172.67.215.2
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Catalyst Pharmaceuticals Partners"
Catalyst: A Biopharmaceutical Company Focused on …
The SUMMIT Study aims to follow patients with DMD 2 years of age and older currently on AGAMREE ® (vamorolone). This 5-year study offers a unique opportunity to evaluate the long-term safety profile of AGAMREE, its impact …See details»
Investors : Catalyst Pharmaceutical
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life …See details»
About Catalyst: Our Management
Richard J. Daly became our President and Chief Executive Officer on January 1, 2024 and has been a member of our Board of Directors since February 2015.See details»
Catalyst Pharmaceuticals - Wikipedia
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in chi…See details»
Catalyst Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 3055290933 Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription …See details»
Catalyst Pharmaceuticals - Overview, News & Similar companies ...
Jun 14, 2024 Catalyst Pharmaceuticals contact info: Phone number: (305) 420-3200 Website: www.catalystpharma.com What does Catalyst Pharmaceuticals do? Catalyst Pharmaceuticals …See details»
Catalyst Pharmaceuticals Inc - Company Profile - GlobalData
Website www.catalystpharma.com Telephone 1 305 5292522. No of Employees 181. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange CPRX (NASD) Revenue (2023) …See details»
Catalyst Pharmaceuticals Announces Appointment of William T
2 days ago Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 [email protected] Media Contact David Schull, Russo Partners (858) 717-2310 …See details»
Press Releases - ir.catalystpharma.com
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 [email protected] Media Contact David Schull, Russo Partners (858) 717-2310 …See details»
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights …
Jan 25, 2023 For more information, visit the Company's website at www.catalystpharma.com. About FYCOMPA FYCOMPA is a prescription medicine used in people with epilepsy aged 4 …See details»
About Catalyst: Our Board of Directors
From 1970 through 2002, Mr. Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit …See details»
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best …
Nov 14, 2024 BioSpace evaluates each organization’s merits with a focus on culture, career growth and development opportunities, leadership, and innovation. Nominations for Best …See details»
Catalyst Pharmaceuticals, Inc. Company Information - Drugs.com
Catalyst Pharmaceuticals, Inc. 355 Alhambra Circle, Suite 801 Coral Gables, FL 33134 Phone: (305) 420-3200 Website: https://catalystpharma.com/ Careers ...See details»
Catalyst Pharmaceuticals Announces Appointment of William
2 days ago Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase …See details»
ESG - catalystpharma.com
At Catalyst, our guiding principle is to create long-term sustainable and collective value for all stakeholders. Since launching our ESG program in 2022, we have made significant strides in …See details»
Press Releases - Catalyst Pharmaceutical
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla. , April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. …See details»
Catalyst Pharmaceuticals Announces Appointment of William T.
2 days ago Gary Ingenito, MD, PhD is retiring from Catalyst after a successful careerCORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. …See details»
Responsibility - catalystpharma.com
To report ethical concerns, ask questions, or seek guidance on Catalyst standards, please visit: www.catalystpharma.ethicspoint.com. Or contact our third-party hotline: United States: (844) …See details»
Catalyst Pharmaceuticals Completes the Acquisition of U.S.
Jan 25, 2023 Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy. Bolsters Presence in NeuroscienceSee details»
Catalyst: Solid Business Model Propels Growth For This Buy And …
4 days ago ir.catalystpharma.com. Its year-over-year Q1 growth comparisons are skewed by the fact that its highest-growing product AGAMREE was not fully launched until Q2, 2024. The …See details»